Insilico Medicine reports a Nature Biotechnology study of rentosertib, a drug for idiopathic pulmonary fibrosis, or IPF. IPF is a scarring lung disease that usually begins around age sixty-five and steadily reduces breathing capacity. The company says both the drug’s target and its chemical structure were found with generative artificial intelligence (AI). The target is TNIK, a protein tied to fibrosis and to several hallmarks of aging, the main processes thought to drive aging. A chemistry program then designed the molecule. Finding the target and naming a preclinical candidate took about eighteen months.
A Phase IIa trial had already met its main safety goal. Forced vital capacity, or FVC, is the amount of air a person can blow out after a full breath. In people over sixty-five, FVC often falls by about twenty to fifty milliliters a year even without IPF. In the sixty-milligram once-daily group, mean FVC rose by 98.4 milliliters, while it fell by 20.3 milliliters on placebo.
What the six clocks showed
The new analysis used stored blood from forty-two patients. Researchers measured 2,841 proteins over twelve weeks and scored biological age with six proteomic aging clocks. A proteomic aging clock estimates how old a person’s protein pattern looks compared with large reference groups. The six clocks all pointed toward a younger predicted age on rentosertib than on placebo. The peak was at week four on thirty milligrams twice daily: about three to four years younger on most clocks, and up to six years on one clock. The dose that helped the lungs most was not the dose that moved the clocks most. The authors take that as a sign that the age-score change is not only a side effect of easier breathing.
Compared with 55,319 UK Biobank profiles, some age-related protein trends appeared to move backward. The text describes a senomorphic effect, meaning the drug dialed down signals of cellular senescence, a state in which damaged cells stop dividing but stay active and inflammatory. The authors present this as a way to add aging measures to ordinary disease trials. The study is small, involves people who already have serious lung disease, and reports predicted age from blood proteins, not longer life.